Tesamorelin Research Overview
Tesamorelin (TH9507) is a modified human growth-hormone-releasing-factor analogue. Its distinctive research feature is an N-terminal structural modification designed to alter degradation and persistence while retaining GHRH-receptor signalling. It is not chemically interchangeable with shorter CJC-1295 No DAC/Modified-GRF-type materials, and a study of a regulated medicinal formulation does not establish anything about a separate Core Research Research Use Only vial.
Research Use Only: This is a molecular and non-clinical evidence guide. It does not give human dosing, administration, treatment or hormone-manipulation instructions.
What makes the TH9507 molecule distinct?
Ferdinandi and colleagues (2007) described TH9507 as an analogue based on human GHRF(1–44)-NH₂ with an N-terminal trans-3-hexenoyl modification. The goal was to reduce susceptibility to dipeptidyl peptidase-IV-related deactivation while maintaining the intended GHRH-receptor pathway.
In comparative non-clinical work, the modified peptide showed slower degradation in the tested rat, dog and human plasma systems than unmodified GHRF. That is a specified chemical and assay-related finding, not a universal stability specification for every finished product or a guarantee of storage behaviour after laboratory reconstitution.
Where does GHRH-receptor signalling fit?
GHRH-receptor activation in relevant pituitary models is associated with cAMP-dependent signal transduction and growth-hormone secretion. A paper reporting a change in a receptor-associated second messenger answers a different question from one measuring plasma growth hormone or a physiological response in an animal.
A sound experimental report therefore states whether the work used a receptor-expression assay, pituitary-cell preparation, plasma degradation system or living-animal model. None of these automatically validates the exact identity, purity, storage or formulation of a marketed research vial.
Non-clinical results and their important adverse findings
The 2007 TH9507 paper compared biochemical persistence and hormonal responses in non-clinical systems, including pigs, rats and dogs. It reported longer apparent exposure and changes in GH/IGF-1-related measurements in those models. The same paper also reported adverse findings in repeat-exposure dog studies, including liver/kidney observations, anaemia and changes in clinical chemistry or organ measurements in the conditions tested.
These findings must be retained alongside the intended biochemical effect. A preclinical paper cannot be reduced to “more stable therefore safer”. The study’s observations do not establish a human safety profile, and they do not support personal use of Core Research material.
| Evidence component | What it tested | Boundary |
|---|---|---|
| Plasma degradation | Behaviour of TH9507 compared with unmodified GHRF in defined plasma systems | Not a shelf-life or solution-stability result for a supplied vial |
| Receptor-pathway context | GHRH-related GH release/signalling | Not direct proof of all organism-level effects |
| Animal exposure | GH/IGF-1 measures and non-clinical pharmacology | Species and formulation matter |
| Repeat-exposure animal findings | Safety observations under studied conditions | Adverse findings cannot be ignored or applied as a human protocol |
Tesamorelin versus CJC-1295 No DAC
The shorter Modified-GRF-type group and TH9507 share a GHRH research pathway, but not identical molecular structures. The difference is not merely a vial label or a “short-acting versus long-acting” marketing description.
| Attribute | Tesamorelin / TH9507 | CJC-1295 No DAC / Modified-GRF-type material |
|---|---|---|
| Sequence framework | Longer GHRF(1–44)-based analogue | Shorter GHRF(1–29)-type analogue |
| Structural approach | N-terminal trans-3-hexenoyl modification | Amino-acid substitutions; no albumin-binding DAC feature by catalogue definition |
| Research identity | TH9507-specific sequence/form | Exact Modified-GRF-type sequence must be separately specified |
| Do half-life results transfer automatically? | No | No |
| Does an external medicinal product validate the RUO item? | No | No |
The CJC-1295 structural comparison explains a third chemically distinct case: published CJC-1295 with an albumin-reactive DAC group. Do not apply that bioconjugate’s exposure data to either TH9507 or the current No-DAC catalogue material.
How to read tesamorelin literature
A laboratory evaluating a source should capture: the exact TH9507 form tested, the comparison molecule, the species or cell system, the measured degradation or signalling endpoint, and whether adverse and null findings were reported. A relative extension of degradation time is not a direct measurement of clinical efficacy or a basis for predicting an experimental concentration in an unrelated protocol.
Do not combine values from animal kinetics, human studies, analytical plasma tests and supplier storage recommendations into one universal tesamorelin “half-life”. Those values arise from different matrices and questions, even when the molecule name overlaps.
What a supplied tesamorelin product record must establish
The relevant laboratory documentation should distinguish the declared sequence and N-terminal chemistry, salt/counter-ion if reported, theoretical versus observed mass and the actual batch’s chromatographic evidence. Identity does not equal content by mass, and an HPLC area percentage cannot alone verify a specific formulation or finished cartridge.
Consult the CoA-reading guide, HPLC interpretation guide and mass-spectrometry identity guide. For a specific supplied material use Batch Documentation.
Core Research catalogue records
The Tesamorelin 10mg vial and Tesamorelin Refill 10mg are separate items. The refill adds finished-format questions, including material compatibility and cartridge specification, which are not answered by a TH9507 pharmacology study. The related growth-signalling research matrix compares study questions, not clinical or performance outcomes.
Selected research reference
Ferdinandi ES et al. Non-clinical pharmacology and safety evaluation of TH9507, a human growth hormone-releasing factor analogue. Basic & Clinical Pharmacology & Toxicology, 2007. DOI: 10.1111/j.1742-7843.2007.00008.x. Includes non-clinical degradation, endocrine and repeat-exposure safety observations.